New technology could lead to safer gene therapy

EU-funded scientists have developed a new, non-viral way of getting genes into a cell. The technique appears to avoid the side-effects, such as cancer, which can occur when viruses are used to smuggle genes into a cell. The scientists hope their discovery will 'simplify the way gene therapy is conducted, improve its overall safety and reduce the costs'.

The findings, published in the journal Nature Genetics, were supported by the EU-funded JUMPY (Transposon-based strategies for functional genomic analyses in Xenopus tropicalis, a vertebrate model system for developmental and biomedical research), INTHER ('Development and application of transposons and site-specific integration technologies as non-viral gene delivery methods for ex vivo gene-based therapies) and PERSIST (Persisting transgenesis) projects.

Gene therapy entails the insertion of genes into a patient's cells; it has proved effective in the treatment of a number of diseases which would otherwise be untreatable. It can be used for hereditary diseases (where a healthy gene is used to replace the faulty gene the patient has inherited), as well as for diseases affecting the heart and brain.

A good gene therapy technique has three characteristics: the therapeutic genes must be delivered to the right cells; the genes must remain active in the patient for a long time; and any undesired side effects should be minimised.

At the moment, viruses are often used as a vector to carry the genes into the target cell. However, this approach is associated with a number of side effects, including inflammation and even the development of cancer. Furthermore, the development of the viral vectors for use in clinical trials is often hampered by technical and regulatory hurdles.

In this latest study, the scientists turned to a natural gene smuggler - the transposons. Transposons are naturally occurring sections of DNA that have the ability to cut and paste themselves into foreign DNA.

The researchers constructed a highly active transposon that is able to carry the therapeutic gene into the target cell and integrate it into the host's DNA.

"We show for the first time that it is now possible to efficiently deliver genes into stem cells, particularly those of the immune system, using non-viral gene delivery," commented Marinee Chuah of the Flanders Institute for Biotechnology (VIB) in Belgium.

"Many groups have tried this for many years but without success. We are glad that we could now overcome this hurdle," added her colleague, Thierry Vandendriessche.

The researchers are now refining and testing their new-found technology for use against specific diseases, including cancer and genetic disorders.

The JUMPY project received EUR 1,183,220 from the 'Quality of life and management of living resources' budget line of the Fifth Framework Programme (FP5), the INTHER project received EUR 2,800,000 from the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6), and the PERSIST project has been allocated EUR 11,181,411 under the Health Theme of the Seventh Framework Programme (FP7).

For more information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Unusual type of antibody shows ultrapotent activit…

An unusual type of antibody that even at miniscule levels neutralizes the Zika virus and renders the virus infection undetectable in preclinical models has been identifie...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...